Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83


Expression features of CXCR5 and its ligand, CXCL13 associated with poor prognosis of advanced colorectal cancer.

Qi XW, Xia SH, Yin Y, Jin LF, Pu Y, Hua D, Wu HR.

Eur Rev Med Pharmacol Sci. 2014 Jul;18(13):1916-24.


Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression.

Razis E, Kalogeras KT, Kotoula V, Eleftheraki AG, Nikitas N, Kronenwett R, Timotheadou E, Christodoulou C, Pectasides D, Gogas H, Wirtz RM, Makatsoris T, Bafaloukos D, Aravantinos G, Televantou D, Pavlidis N, Fountzilas G.

Clin Breast Cancer. 2012 Jun;12(3):183-93. doi: 10.1016/j.clbc.2012.03.006. Erratum in: Clin Breast Cancer. 2012 Oct;12(5):386.


CXCL13-CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis.

Biswas S, Sengupta S, Roy Chowdhury S, Jana S, Mandal G, Mandal PK, Saha N, Malhotra V, Gupta A, Kuprash DV, Bhattacharyya A.

Breast Cancer Res Treat. 2014 Jan;143(2):265-76. doi: 10.1007/s10549-013-2811-8. Epub 2013 Dec 13. Erratum in: Breast Cancer Res Treat. 2016 Feb;155(3):615-6.


Altered expression of the receptor-ligand pair CXCR5/CXCL13 in B cells during chronic HIV-1 infection.

Cagigi A, Mowafi F, Phuong Dang LV, Tenner-Racz K, Atlas A, Grutzmeier S, Racz P, Chiodi F, Nilsson A.

Blood. 2008 Dec 1;112(12):4401-10. doi: 10.1182/blood-2008-02-140426. Epub 2008 Sep 9.


Expression of CIAPIN1 in human colorectal cancer and its correlation with prognosis.

Shi H, Zhou Y, Liu H, Chen C, Li S, Li N, Li X, Zhang X, Zhang H, Wang W, Zhao Q.

BMC Cancer. 2010 Sep 3;10:477. doi: 10.1186/1471-2407-10-477.


Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia.

Bürkle A, Niedermeier M, Schmitt-Gräff A, Wierda WG, Keating MJ, Burger JA.

Blood. 2007 Nov 1;110(9):3316-25. Epub 2007 Jul 25.


CXCL13-CXCR5 axis promotes the growth and invasion of colon cancer cells via PI3K/AKT pathway.

Zhu Z, Zhang X, Guo H, Fu L, Pan G, Sun Y.

Mol Cell Biochem. 2015 Feb;400(1-2):287-95. doi: 10.1007/s11010-014-2285-y. Epub 2014 Dec 5.


The association of CXCR4 expression with prognosis and clinicopathological indicators in colorectal carcinoma patients: a meta-analysis.

Lv S, Yang Y, Kwon S, Han M, Zhao F, Kang H, Dai C, Wang R.

Histopathology. 2014 Apr;64(5):701-12. doi: 10.1111/his.12321. Epub 2014 Jan 15. Erratum in: Histopathology. 2014 Jun;64(7):1047.


Expression of ZNF148 in different developing stages of colorectal cancer and its prognostic value: a large Chinese study based on tissue microarray.

Gao XH, Liu QZ, Chang W, Xu XD, Du Y, Han Y, Liu Y, Yu ZQ, Zuo ZG, Xing JJ, Cao G, Fu CG.

Cancer. 2013 Jun 15;119(12):2212-22. doi: 10.1002/cncr.28052. Epub 2013 Apr 10.


Podoplanin expression identified in stromal fibroblasts as a favorable prognostic marker in patients with colorectal carcinoma.

Yamanashi T, Nakanishi Y, Fujii G, Akishima-Fukasawa Y, Moriya Y, Kanai Y, Watanabe M, Hirohashi S.

Oncology. 2009;77(1):53-62. doi: 10.1159/000226112. Epub 2009 Jun 25.


Serum BLC/CXCL13 concentrations and renal expression of CXCL13/CXCR5 in patients with systemic lupus erythematosus and lupus nephritis.

Lee HT, Shiao YM, Wu TH, Chen WS, Hsu YH, Tsai SF, Tsai CY.

J Rheumatol. 2010 Jan;37(1):45-52. doi: 10.3899/jrheum.090450. Epub 2009 Dec 1.


The Expression and Significance of CXCR5 and MMP-13 in Colorectal Cancer.

Yan Q, Yuan Y, Yankui L, Jingjie F, Linfang J, Yong P, Dong H, Xiaowei Q.

Cell Biochem Biophys. 2015 Sep;73(1):253-9. doi: 10.1007/s12013-015-0624-6.


Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells.

Wang L, Shi S, Guo Z, Zhang X, Han S, Yang A, Wen W, Zhu Q.

PLoS One. 2013 Jun 10;8(6):e65539. doi: 10.1371/journal.pone.0065539. Print 2013.


Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients.

Panse J, Friedrichs K, Marx A, Hildebrandt Y, Luetkens T, Barrels K, Horn C, Stahl T, Cao Y, Milde-Langosch K, Niendorf A, Kröger N, Wenzel S, Leuwer R, Bokemeyer C, Hegewisch-Becker S, Atanackovic D.

Br J Cancer. 2008 Sep 16;99(6):930-8. doi: 10.1038/sj.bjc.6604621.


Overexpression of RhoGDI2 correlates with tumor progression and poor prognosis in colorectal carcinoma.

Li X, Wang J, Zhang X, Zeng Y, Liang L, Ding Y.

Ann Surg Oncol. 2012 Jan;19(1):145-53. doi: 10.1245/s10434-011-1944-4. Epub 2011 Aug 23.


Role of CXCL13-CXCR5 crosstalk between malignant neuroblastoma cells and Schwannian stromal cells in neuroblastic tumors.

Del Grosso F, Coco S, Scaruffi P, Stigliani S, Valdora F, Benelli R, Salvi S, Boccardo S, Truini M, Croce M, Ferrini S, Longo L, Tonini GP.

Mol Cancer Res. 2011 Jul;9(7):815-23. doi: 10.1158/1541-7786.MCR-10-0367. Epub 2011 Jun 3.


High expression level and nuclear localization of Sam68 are associated with progression and poor prognosis in colorectal cancer.

Liao WT, Liu JL, Wang ZG, Cui YM, Shi L, Li TT, Zhao XH, Chen XT, Ding YQ, Song LB.

BMC Gastroenterol. 2013 Aug 9;13:126. doi: 10.1186/1471-230X-13-126.


Lgr5 over-expression is positively related to the tumor progression and HER2 expression in stage pTNM IV colorectal cancer.

Gao FJ, Chen JY, Wu HY, Shi J, Chen M, Fan XS, Huang Q.

Int J Clin Exp Pathol. 2014 Mar 15;7(4):1572-9. eCollection 2014.


High KLF4 level in normal tissue predicts poor survival in colorectal cancer patients.

Lee HY, Ahn JB, Rha SY, Chung HC, Park KH, Kim TS, Kim NK, Shin SJ.

World J Surg Oncol. 2014 Jul 24;12:232. doi: 10.1186/1477-7819-12-232.


Expression of EGFR, Her2 predict lymph node metastasis (LNM)-associated metastasis in colorectal cancer.

Lu Y, Jingyan G, Baorong S, Peng J, Xu Y, Cai S.

Cancer Biomark. 2012;11(5):219-26. doi: 10.3233/CBM-2012-00282.


Supplemental Content

Support Center